168 related articles for article (PubMed ID: 14671932)
1. [Pathogenic bacteria in cystic fibrosis].
Mariani-Kurkdjian P; Bingen E
Arch Pediatr; 2003 Sep; 10 Suppl 2():342s-346s. PubMed ID: 14671932
[TBL] [Abstract][Full Text] [Related]
2. [Bronchopulmonary infection in cystic fibrosis].
Munck A; Bingen E
Rev Prat; 2003 Jan; 53(2):145-50. PubMed ID: 12664845
[TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.
Vu-Thien H; Moissenet D; Valcin M; Dulot C; Tournier G; Garbarg-Chenon A
Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):876-9. PubMed ID: 8997562
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
5. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.
Beringer PM; Appleman MD
Curr Opin Pulm Med; 2000 Nov; 6(6):545-50. PubMed ID: 11100967
[TBL] [Abstract][Full Text] [Related]
6. Bacteriology and antibiotic resistance in chronic rhinosinusitis.
Manes RP; Batra PS
Facial Plast Surg Clin North Am; 2012 Feb; 20(1):87-91. PubMed ID: 22099621
[TBL] [Abstract][Full Text] [Related]
7. Antibody response to Burkholderia cepacia in patients with cystic fibrosis colonized with Burkholderia cepacia and Pseudomonas aeruginosa.
Hendry J; Butler S; Elborn JS; Govan JR; Nelson J; Shale DJ; Webb AK
J Infect; 2000 Mar; 40(2):164-70. PubMed ID: 10841094
[TBL] [Abstract][Full Text] [Related]
8. The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Zobell JT; Kemper AL; Young DC
Pediatr Pulmonol; 2014 Mar; 49(3):E48-51. PubMed ID: 23661625
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
[TBL] [Abstract][Full Text] [Related]
10. Microbiology of lung infection in cystic fibrosis.
Govan JR; Nelson JW
Br Med Bull; 1992 Oct; 48(4):912-30. PubMed ID: 1281036
[TBL] [Abstract][Full Text] [Related]
11. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
Govan JR; Brown AR; Jones AM
Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
[TBL] [Abstract][Full Text] [Related]
12. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
Coman G; Petraru E; Dahorea C; Anton DT
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
[TBL] [Abstract][Full Text] [Related]
13. Emerging and unusual gram-negative infections in cystic fibrosis.
Davies JC; Rubin BK
Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
[TBL] [Abstract][Full Text] [Related]
14. The cystic fibrosis lung microbiome.
Surette MG
Ann Am Thorac Soc; 2014 Jan; 11 Suppl 1():S61-5. PubMed ID: 24437409
[TBL] [Abstract][Full Text] [Related]
15. [ANTIBIOTICS SENSITIVITY OF STAPHYLOCOCCUS AUREUS, PSEUDOMONAS AERUGINOSA AND BACTERIA OF BURKHOLDERIA CEPACIA COMPLEX, PERSISTING IN LUNGS OF PATIENTS WITH MUCOVISCIDOSIS (MV)].
Avetisyan LR; Chernukha MY; Shaginyan IA; Kapranov NI; Siyanova EA; Medvedeva OS; Kondratieva EI; Alekseeva GV; Krasovsky SA; Usacheva MV; Amelina EL
Zh Mikrobiol Epidemiol Immunobiol; 2015; (6):3-10. PubMed ID: 26950982
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis.
Kurlandsky LE; Fader RC
Pediatr Pulmonol; 2000 Mar; 29(3):210-2. PubMed ID: 10686042
[TBL] [Abstract][Full Text] [Related]
17. Microbiology of airway disease in a cohort of patients with cystic fibrosis.
Lambiase A; Raia V; Del Pezzo M; Sepe A; Carnovale V; Rossano F
BMC Infect Dis; 2006 Jan; 6():4. PubMed ID: 16405721
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the biocide Steri-7 against the common Gram-negative bacterial pathogens (Burkholderia cenocepacia, Burkholderia gladioli, Burkholderia multivorans, Pseudomonas aeruginosa and Stenotrophomonas maltophilia) associated with cystic fibrosis (CF).
Moore JE; Rao JR
Br J Biomed Sci; 2013; 70(2):80-1. PubMed ID: 23888610
[No Abstract] [Full Text] [Related]
19. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
Rutter WC; Burgess DR; Burgess DS
Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
[TBL] [Abstract][Full Text] [Related]
20. A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection.
Mc Manus TE; Moore JE; Crowe M; Dunbar K; Elborn JS
J Infect; 2003 Jan; 46(1):56-9. PubMed ID: 12504610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
